Detailed Description

AZELTA – a direct antiviral agent that:

• Eases the course of influenza¹
• Reduces the duration of illness^1,2,3,4
• Lowers the risk of complications (such as lower respiratory tract diseases requiring antibiotic therapy, acute otitis media, etc.)^2,3

Oseltamivir is included in authoritative recommendations and protocols for influenza treatment:

• Recommendations from the American Academy of Pediatrics (AAP) for influenza prevention and control in children, 2019-2020;
• Practical clinical guidelines from the Infectious Diseases Society of America (IDSA) on the diagnosis, chemoprophylaxis, and treatment of seasonal influenza (2018);
• Scientific recommendations from the European Centre for Disease Prevention and Control (ECDC 2017), as well as national guidelines from 20 EU member states;
• Practical clinical guidance from the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) on the diagnosis and treatment of pneumonia in adults (2019);

as well as in

• Unified clinical protocol for primary and secondary (specialized) medical care for adults and children “Influenza”, approved by the Order of the Ministry of Health of Ukraine No. 499 dated 16.07.2014.

1. T. Jefferson, M. Jones, P. Doshi et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348:g2545.
2. J. Dobson, R. J. Whitley, S. Pocock et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomized controlled trials. Lancet. 2015 May 2;385(9979):1729-1737.
3. R.E. Malosh, E.T. Martin, T. Heikkinen et al. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis. 2018 May 2;66(10):1492-1500.
4. C.C. Butler, A.W. van der Velden, E. Bongard et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomized controlled trial. Lancet. 2020 Jan 4;395(10217):42-52. doi: 10.1016/S0140-6736(19)32982-4. Epub 2019 Dec 12.

For more detailed information about the medication Azelta, you can refer to the package leaflet.

Registration certificate of the Ministry of Health of Ukraine № UA/18115/01/01 dated 13.05.2020